Martin Barrett

1.0k total citations · 1 hit paper
17 papers, 684 citations indexed

About

Martin Barrett is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Martin Barrett has authored 17 papers receiving a total of 684 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 10 papers in Genetics and 10 papers in Oncology. Recurrent topics in Martin Barrett's work include Lymphoma Diagnosis and Treatment (12 papers), Chronic Lymphocytic Leukemia Research (10 papers) and CAR-T cell therapy research (5 papers). Martin Barrett is often cited by papers focused on Lymphoma Diagnosis and Treatment (12 papers), Chronic Lymphocytic Leukemia Research (10 papers) and CAR-T cell therapy research (5 papers). Martin Barrett collaborates with scholars based in United Kingdom, Switzerland and Italy. Martin Barrett's co-authors include Michael Wenger, Susan O’Brien, Gilles Salles, David G. Maloney, Nancy Valente, Robin Foà, J Maurer, Claude Berge, Francesco Merli and David MacDonald and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Martin Barrett

17 papers receiving 672 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

2017 396 citations Gilles Salles, Martin Barrett et al. Advances in Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Martin Barrett United Kingdom	10	334	316	200	196	165	17	684
Mimi Folden Flensburg Denmark	7	187 0.6×	374 1.2×	191 1.0×	337 1.7×	202 1.2×	10	566
Wilhelmina M. Aarts Netherlands	11	246 0.7×	351 1.1×	363 1.8×	227 1.2×	110 0.7×	13	726
S. Poppema Netherlands	13	268 0.8×	448 1.4×	262 1.3×	186 0.9×	116 0.7×	15	695
Don A. Stevens United States	15	469 1.4×	232 0.7×	146 0.7×	149 0.8×	61 0.4×	100	798
Kouji Oka Japan	14	433 1.3×	545 1.7×	228 1.1×	152 0.8×	30 0.2×	18	727
Keitaro Tsushita Japan	12	412 1.2×	429 1.4×	124 0.6×	240 1.2×	47 0.3×	25	818
Franciane Paul France	9	196 0.6×	113 0.4×	275 1.4×	149 0.8×	63 0.4×	18	557
Deborah B. Aquino United States	9	165 0.5×	217 0.7×	211 1.1×	143 0.7×	50 0.3×	10	651
RA Warnke United States	14	345 1.0×	531 1.7×	365 1.8×	257 1.3×	162 1.0×	31	992
Ayse U. Akarca United Kingdom	14	475 1.4×	196 0.6×	253 1.3×	44 0.2×	53 0.3×	34	773

Countries citing papers authored by Martin Barrett

Since Specialization

Citations

This map shows the geographic impact of Martin Barrett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Barrett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Barrett more than expected).

Fields of papers citing papers by Martin Barrett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Barrett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Barrett. The network helps show where Martin Barrett may publish in the future.

Co-authorship network of co-authors of Martin Barrett

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Barrett. A scholar is included among the top collaborators of Martin Barrett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Barrett. Martin Barrett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Topp, Max S., Monica Tani, Michael Dickinson, et al.. (2025). 280 | GLOFITAMAB COMBINED WITH R‐CHOP OR POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA: FINAL RESULTS FROM THE NP40126 STUDY. Hematological Oncology. 43(S3). 1 indexed citations

Townsend, William, Max S. Topp, Michael Dickinson, et al.. (2023). Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non‐Hodgkin lymphoma (R/R NHL): update of a Phase Ib study. Hematological Oncology. 41(S2). 595–597. 1 indexed citations

Dickinson, Michael, Andreas Viardot, Reinhard Marks, et al.. (2023). Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.. Journal of Clinical Oncology. 41(16_suppl). 7549–7549. 16 indexed citations

Topp, Max S., Monica Tani, Michael Dickinson, et al.. (2023). Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study. Blood. 142(Supplement 1). 3085–3085. 15 indexed citations

Topp, Max S., Monica Tani, Michael Dickinson, et al.. (2022). Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study. Blood. 140(Supplement 1). 1775–1777. 19 indexed citations

Ghosh, Nilanjan, William Townsend, Michael Dickinson, et al.. (2021). Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study. Blood. 138(Supplement 1). 2479–2479. 10 indexed citations

Jamois, Candice, Ekaterina Gibiansky, Leonid Gibiansky, et al.. (2021). Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies. Clinical Pharmacology & Therapeutics. 110(5). 1261–1272. 4 indexed citations

Davies, Andrew, Francesco Merli, Biljana Mihaljević, et al.. (2017). Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. The Lancet Haematology. 4(6). e272–e282. 83 indexed citations

Salles, Gilles, Martin Barrett, Robin Foà, et al.. (2017). Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Advances in Therapy. 34(10). 2232–2273. 396 indexed citations breakdown →

10.

Davies, Andrew, Biljana Mihaljević, Santiago Mercadal, et al.. (2016). Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of the Phase 3 SABRINA Study. Blood. 128(22). 1103–1103. 1 indexed citations

11.

Palermo, Giuseppe, Daniela Maisel, Martin Barrett, et al.. (2015). Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia. Blood Cancer Journal. 5(10). e353–e353. 5 indexed citations

12.

Davies, Andrew, Francesco Merli, Biljana Mihaljević, et al.. (2014). Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. The Lancet Oncology. 15(3). 343–352. 90 indexed citations

13.

Davies, Andrew, Francesco Merli, Noppadol Siritanaratkul, et al.. (2012). Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334). Blood. 120(21). 1629–1629. 7 indexed citations

14.

Molife, R., Heather M. Shaw, William P. Steward, et al.. (2006). Phase I dose-escalation study of ZK 304709, an oral multi-target tumor growth inhibitor (MTGI), administered for 14 days of a 28-day cycle. Journal of Clinical Oncology. 24(18_suppl). 2076–2076. 9 indexed citations

15.

Barrett, Martin, F. Jackson, & J.F. Huntley. (1998). Pathogenicity and immunogenicity of different isolates of Teladorsagia circumcincta. Veterinary Parasitology. 76(1-2). 95–104. 11 indexed citations

16.

Barrett, Martin, et al.. (1998). Comparative field evaluation of divided-dosing and reduced feed intake upon treatment efficacy against resistant isolates of Teladorsagia circumcincta in sheep and goats. Research in Veterinary Science. 64(2). 101–104. 6 indexed citations

17.

Milford, David V., Amanda Goldstein, Martin Barrett, Jillian R. Mann, & F. Raafat. (1993). Cancer associated haemolytic uraemic syndrome developing prior to treatment with cytotoxic agents. Medical and Pediatric Oncology. 21(2). 142–145. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact